{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-036386","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.521816+00:00","generated_at":"2026-05-15T08:26:30.732001+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alumis Phase 3 envudeucitinib hits PASI 90/100 endpoints in plaque psoriasis","bullets":["PASI 90 at Week 24: 68.0% (ONWARD1) and 62.1% (ONWARD2); PASI 100: 41.0% and 39.5%.","Early onset: PASI 90 separation vs placebo by Week 4; itch relief by Week 2; scalp clearance in ~30% by Week 4.","Safety profile consistent with Phase 2; no new signals, mainly mild AEs (headache, nasopharyngitis, URTI, acne).","Company to submit NDA to FDA in H2 2026; Phase 3 long-term extension (ONWARD3) ongoing.","Also evaluating envudeucitinib in SLE LUMUS Phase 2b with topline data expected Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-036386","json":"https://secwatch.observer/filing/0001104659-26-036386.json","markdown":"https://secwatch.observer/filing/0001104659-26-036386.md","text":"https://secwatch.observer/filing/0001104659-26-036386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/0001104659-26-036386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:26:30.732001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}